Market Research Logo

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016’, provides in depth analysis on Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted pipeline therapeutics.

The report provides comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR)
  • The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) Overview
Therapeutics Development
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Stage of Development
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Therapy Area
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Indication
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Companies
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Companies Involved in Therapeutics Development
Alder Biopharmaceuticals Inc.
Ipsen S.A.
Mallinckrodt Plc
Pfizer Inc.
Retrophin Inc.
XOMA Corporation
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Drug Profiles
ALD-1613 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Dormant Projects
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Discontinued Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Featured News & Press Releases
Apr 03, 2016: Alder Presents Preclinical Data for ALD1613 at ENDO 2016
Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus
Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology
Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology
Mar 27, 2015: Positive Outcomes With H.P. Acthar Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congress
Jan 06, 2015: BioSim Pharmaceuticals to meet with Industry during JP Morgan Healthcare Conference
May 05, 2014: Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
Apr 21, 2014: Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
Jul 24, 2013: Questcor to Commence Phase 2 Study of Acthar for ALS
Jul 11, 2013: Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
Jun 14, 2012: Questcor Pharma Announces Initial Commercialization Plans For Acthar Rheumatology Indications
Nov 10, 2011: New Research Suggests Questcor's Acthar Reduces Proteinuria In Idiopathic Membranous Nephropathy In Part Through Suppression Of Anti-PLA2R Antibodies
Oct 15, 2010: Questcor Receives FDA Approval For H.P. Acthar Gel For Treatment Of Infantile Spasms
Sep 08, 2010: Questcor Updates Status Of Supplemental New Drug Application For H.P. Acthar Gel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Alder Biopharmaceuticals Inc., H1 2016
Pipeline by Ipsen S.A., H1 2016
Pipeline by Mallinckrodt Plc, H1 2016
Pipeline by Pfizer Inc., H1 2016
Pipeline by Retrophin Inc., H1 2016
Pipeline by XOMA Corporation, H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report